Cordis Corp., one of the most powerful players in coronary stents and the first to bring a drug-eluting stent to market is getting out of the business. The Johnson & Johnson (NYSE:JNJ) subsidiary, announced Wednesday morning that it will drop its stent business entirely, including work on novel DES designs. Since news of the announcement […]
Johnson & Johnson's Cordis Corp. subsidiary, which makes the Cypher drug-eluting stent, confirmed that it will lay off some of its sales force and merge two sales operations in response to sliding Cypher sales. Also, C.R. Bard Inc. is cutting 200 jobs at a Queensbury, N.Y., plant.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Cordis Corp., the stent-making operation of Johnson & Johnson (NYSE:JNJ), saw overall sales slip nearly 7 percent and stent sales drop 35.5 percent during the third quarter. The New Brunswick, New Jersey-based medical products conglomerate said Cordis posted worldwide sales of $596 million during the three months ended Sept. 30, down 6.9 percent compared with […]
Wall Cardiovascular Technologies LLC agrees to settle a patent infringement lawsuit it filed against Medtronic Inc. and Boston Scientific Inc., leaving Johnson & Johnson’s Cordis Corp. and Abbott as the only remaining defendants. Wall Cardiovascular Technologies LLC agreed to settlements with two of the four major drug-eluting stent makers it’s accused of patent infringement, leaving […]
Citing results from the Sort Out IV trial, a head-to-head comparison of the two drug-eluting stents, Cordis chief scientific officer Dr. Campbell Rogers said the study confirms "the excellent sustained clinical outcomes consistently seen over the last 10 years." "The Sort Out consortium has used Cypher stent as the comparator in a number of studies and, to date, no newer stent has proven a benefit over Cypher stent in terms of safety or efficacy," Rogers said in prepared remarks.
Johnson & Johnson (NYSE:JNJ) provided investors and analysts with a glimpse into its medical device operation, which it called the world’s largest. Over the past two years, according to the presentation, the division posted $1.8 billion in operational sales growth (excluding special items such as acquisitions or legal expenses). The segment’s total sales during the […]
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
A federal judge in Delaware declared invalid a quartet of Johnson & Johnson's Cordis Corp. subsidiary's patents for drug-eluting stents, canceling a trial set for next month in a patent infringement lawsuit filed by Boston Scientific.
Cordis Corp. will defend the Cypher drug-eluting stent on its home turf in New Jersey in a patent infringement case against Boston Scientific Corp. and Abbott Laboratories.
Some of the biggest names in medical devices are embroiled in a whistleblower lawsuit accusing them of deliberately promoting the off-label use of biliary stents to treat cardiovascular conditions in hundreds of thousands of patients.